Exco InTouch Achieve a New First in Mobile Clinical Technology
Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers has announced a new first in the clinical technology arena. Having pioneered the use of mobile technology, increasing retention and compliance through engaging and supporting patients, and facilitating the delivery of ePRO via mobile devices, the forward looking company are now the only electronic Clinical Outcomes Assessment (eCOA) provider to have published public-facing apps on all three mobile operating platforms (iOS, Android and Windows8).
Dale Jessop, CTO at Exco InTouch, commented: “We’re thrilled to have reached this milestone, and even more so having used native apps, as this provides the user with device specific natural controls — driving familiarity and ease of use. Currently the most common approach is to use HTML5, which wraps a web app into mobile operating controls, however, this does not enable the layout to be optimised for the device in use, or incorporate natural button configurations and so does not present the best experience for patients. In contrast, our pedigree in developing mobile solutions for clinical and healthcare programs has enabled us to deliver the benefits of native apps in a timely, cost effective manner across all platforms.”
The variety of apps developed for clients by Exco InTouch covers a broad range of therapeutic areas, from cardiovascular and respiratory diseases through to smoking cessation and vaccination programmes, utilising their flexible platform which adapts to individual programme needs. The platform enables the integration of medical device data and also lifestyle devices, such as FitBit, which are increasingly popular in clinical research to provide secondary outcomes data.
The company’s leading approach enables its clients to select their preferred delivery model, offering the flexibility to either provision appropriate devices for the study population, or more significantly to enable BYOD (Bring Your Own Device) in both clinical and commercial programs. This is enabled by proprietary mDNA technology, which provides sponsors and payers the robust reassurance of protecting Personally Identifiable Information (PII) and maintaining data security even when using the patients’ own devices.
Tim Davis, CEO and founder of Exco InTouch, commented: “We are leading the way in delivering native apps across all three mobile operating platforms, which not only is an achievement for our company, but also another great milestone for the entire clinical industry. There is huge demand in the industry for eCOA providers to deliver user friendly solutions that the patient finds easy to use and accessible. A clinical trial is reliant on timely engagement from its patients and we are delighted to be foremost in improving patients’ user experience.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance